Listen on the go
Downloads

View and download resources from this activity to support your learning or share with colleagues.

Download Slides
CORRECT!
Next question
touchOPHTHALMOLOGY touchOPHTHALMOLOGY

nAMD

Watch interviews and expert perspectives on the latest data on the clinical management of neovascular age-related macular degeneration (nAMD).

Curriculum Activities

Macular Degeneration
Watch Time: 53 mins
touchCONGRESS
Holistic approaches to patient care in nAMD
Prof. Anat Loewenstein, Dr Carl Regillo, Dr Patricia Udaondo

Watch this two-part activity discussing the latest developments in the clinical management of neovascular age-related macular degeneration (nAMD), filmed following the European Society of Retina Specialists (EURETINA) 2020 Virtual Congress Part 1: Watch internationally renowned expert Prof. Anat Loewenstein review the key data on nAMD from the congress Watch Now Part 2: Choose from leading experts who discuss what the data means for global and regional practice Select An Interview

Learning objectives
Learning Objectives
  • Evaluate the use of retinal fluid as a marker of disease activity in neovascular age-related macular degeneration (nAMD)
  • Recognize the impact of factors that contribute to treatment discontinuation and evaluate ways to reduce the treatment burden in nAMD
  • Interpret results from clinical trials and real-world experience to inform on optimal dosing of anti-vascular endothelial growth factor (VEGF) therapy in nAMD
Macular Degeneration
Watch Time: 40 mins
touchCONGRESS
Will a scientific breakthrough translate into clinical benefits in nAMD? Highlights from EURETINA 2019
Prof. Anat Lowenstein, Prof. Pravin Dugel, Prof. Eric Souied

Stay up to date with the latest developments in the management and treatment of patients with nAMD with our expert summary from the 19th EURETINA Congress in Paris, France, 5–8 September 2019. Part 1: Watch internationally renowned expert Prof. Anat Loewenstein review key data from EURETINA 2019 Part 2: Choose from leading experts who discuss what data findings mean for global and regional practice

Learning objectives
Learning Objectives
  • Illustrate how retinal fluid may be used as a marker of disease activity and to guide individualized therapeutic strategy
  • Define the importance of patient adherence to treatment on clinical outcomes and the factors that impact adherence and QoL
  • Explain how smaller sized anti-VEGF antibodies may address the real-life unmet needs and confer clinical benefits
IME
Education activities are developed by touchIME for touchOPHTHALMOLOGY.

Our education resources are developed in collaboration with our well established peer-reviewed medical journals, our Editorial Board members and partnerships with major medical societies, with a clear commitment to high-quality independent education.

Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72